The Ugandan AIDS Rural Treatment Outcomes study was funded by U.S. National Institutes of Health (NIH) R01 MH-054907, K23 MH-079713, K23 MH-079713-03S1, and P30 AI-027763. Dr. Kruse was supported by grant T32HP12706-03-00 from the Health Resources and Services Administration for the Harvard General Medicine Fellowship and the Ryoichi Sasakawa Fellowship Fund. Dr. Bangsberg was funded by NIH grant K24 MH87227. Dr. Haberer was funded by NIH grant K23 087228.
AIDS and Behavior
Smoking cessation, AIDS (Disease) -- Patients -- Tobacco use, AIDS (Disease) -- Uganda -- Treatment, Antiretroviral treatment
We conducted a longitudinal study of tobacco use among adults initiating antiretroviral therapy (ART) in Mbarara, Uganda where 11% of men and 3% of women use tobacco according to the 2011 Demographic and Health Survey. In a prospective cohort, self-reported tobacco use was assessed before starting ART and reassessed every 3–4 months. Plasma cotinine, a nicotine metabolite, was measured in a subset of adults pre-ART to verify self-report. Among 496 subjects, 50 (10%) reported current tobacco use (20% of men, 6% of women). Most (53%) adults with elevated cotinine levels (>15 ng/mL) reported no tobacco use. By 6 months after ART initiation, 33% of tobacco users had quit (95% CI=20–46%). By 5 years, 64% quit (95% CI=47–77%). Self-reported tobacco use among rural Ugandans starting ART was twice as common as among the local background population and use may be underreported. ART initiation could be an opportunity for tobacco cessation interventions.
Kruse GR, Bangsberg DR, Hahn JA, Haberer JE, Hunt PW, Muzoora C, Bennett JP, Martin JN, Rigotti NA. Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda. AIDS Behav. 2014 Mar 18.